OnKure (OKUR) Director Liam Ratcliffe Receives Award for 22,350 Shares

What Happened

• Liam Ratcliffe, a director of OnKure Therapeutics (OKUR), received a derivative award for 22,350 shares on 2026-08-07. The award is reported at $0.00 per share (no cash paid), indicating a grant of equity compensation (e.g., stock options or RSUs) rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-08-07; Form 4 filed: 2026-08-11.
• Quantity: 22,350 shares granted; reported price: $0.00; total cash value shown: $0.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the issuer’s next annual meeting of stockholders, subject to continued service.
• Timeliness: Filing was posted four days after the reported transaction. Form 4s are generally required within two business days, so this appears later than typical.

Context

• The filing classifies this as a derivative award, which commonly means stock options or restricted stock units; the Form 4 does not indicate any immediate sale or cashless exercise. Grants are typically used to align management/directors with shareholder interests but do not itself signal buying or selling.